M3（4YC）株式概要エムスリー株式会社は、主にインターネットを通じて医師やその他の医療従事者に医療関連サービスを提供しています。 詳細4YC ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長2/6過去の実績3/6財務の健全性5/6配当金4/6報酬株価収益率（ 26.2 x）は、 Healthcare Services業界平均（ 28.3 x）を下回っています。収益は年間10.9%増加すると予測されています 過去1年間で収益は21.3%増加しました リスク分析リスクチェックの結果、4YC 、リスクは検出されなかった。すべてのリスクチェックを見る4YC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,833 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG484,833 investors already sharing narrativesYour Fair Value€Current Price€10.1018.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0545b2016201920222025202620282031Revenue JP¥545.2bEarnings JP¥76.2bAdvancedSet Fair ValueView all narrativesM3, Inc. 競合他社CompuGroup Medical SE KGaASymbol: HMSE:COPMarket cap: €1.4bDocCheckSymbol: XTRA:AJ91Market cap: €60.4mFresenius Medical CareSymbol: XTRA:FMEMarket cap: €11.2bMeVis Medical SolutionsSymbol: XTRA:M3VMarket cap: €44.0m価格と性能株価の高値、安値、推移の概要M3過去の株価現在の株価JP¥10.1052週高値JP¥15.1052週安値JP¥7.04ベータ0.471ヶ月の変化19.64%3ヶ月変化20.30%1年変化-6.48%3年間の変化-47.67%5年間の変化n/aIPOからの変化-68.91%最新ニュースお知らせ • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026お知らせ • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026お知らせ • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026最新情報をもっと見るRecent updatesお知らせ • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026お知らせ • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026お知らせ • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026お知らせ • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.お知らせ • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.お知らせ • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025お知らせ • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury sharesお知らせ • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.お知らせ • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.お知らせ • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025お知らせ • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.お知らせ • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €10.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.60 per share.お知らせ • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €8.75, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €14.82 per share.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €7.45, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €14.26 per share.Reported Earnings • Jul 29First quarter 2025 earnings released: EPS: JP¥16.57 (vs JP¥18.29 in 1Q 2024)First quarter 2025 results: EPS: JP¥16.57 (down from JP¥18.29 in 1Q 2024). Revenue: JP¥64.2b (up 12% from 1Q 2024). Net income: JP¥11.2b (down 9.4% from 1Q 2024). Profit margin: 18% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.お知らせ • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.Buy Or Sell Opportunity • Apr 25Now 20% overvaluedOver the last 90 days, the stock has fallen 25% to €11.20. The fair value is estimated to be €9.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Board Change • Mar 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.株主還元4YCDE Healthcare ServicesDE 市場7D0.1%-0.3%0.7%1Y-6.5%10.9%0.6%株主還元を見る業界別リターン: 4YC過去 1 年間で10.9 % の収益を上げたGerman Healthcare Services業界を下回りました。リターン対市場: 4YCは、過去 1 年間で0.6 % のリターンを上げたGerman市場を下回りました。価格変動Is 4YC's price volatile compared to industry and market?4YC volatility4YC Average Weekly Movement6.0%Healthcare Services Industry Average Movement5.1%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.8%安定した株価: 4YC 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4YCの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200017,010Itaru Tanimuracorporate.m3.comエムスリー株式会社は、主にインターネットを通じて医師やその他の医療従事者に医療関連サービスを提供している。同社は5つの報告セグメントを通じて事業を展開している：メディカル・プラットフォーム事業」、「エビデンス・ソリューション事業」、「キャリア・ソリューション事業」、「サイト・ソリューション事業」、「海外事業」の5つを報告セグメントとしている。医療従事者向けの会員制情報提供サイト「m3.com」、会員医師がm3comプラットフォーム上で独自に継続的に情報提供を受けることができる「MR君」、医療情報以外のライフサポート情報を会員に提供する「QOL君」、登録医師が一般からの健康や病気に関する質問に回答する「AskDoctors」、米国の医療従事者向けサイト「MDLinx」、製薬企業向けの開発サービスやフランス、ドイツ、スペインで医薬品情報データベースを提供するサイト「Doctors.net.uk」などを運営している。また、m3.com CAREERを通じて、医師・薬剤師向けのキャリアサービス、人材紹介、求人広告の掲載も行っている。その他、医薬品・医療機器の販売活動及びマーケティング事業、医療機関向け電子カルテ・医療機器の開発・販売・サポート事業、医療従事者向け調査サービス事業、インターネットを通じた製薬企業等の販売・マーケティング支援事業、医療機関向け経営支援・コンサルティングサービス及び訪問看護サービスの提供、医療従事者向け人材サービスの提供、治験施設の運営等を行っています。また、エムスリー株式会社は、医療従事者向けに臨床・医療・政治に関するニュースや教育を提供している。エムスリーの前身はソネット・エムスリー株式会社で、2010年1月にエムスリーに社名を変更した。エムスリーは2000年に設立され、東京に本社を置いている。もっと見るM3, Inc. 基礎のまとめM3 の収益と売上を時価総額と比較するとどうか。4YC 基礎統計学時価総額€6.92b収益（TTM）€264.24m売上高(TTM)€1.89b26.2xPER（株価収益率3.7xP/Sレシオ4YC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4YC 損益計算書（TTM）収益JP¥351.36b売上原価JP¥175.52b売上総利益JP¥175.84bその他の費用JP¥126.74b収益JP¥49.10b直近の収益報告Mar 31, 2026次回決算日Aug 06, 2026一株当たり利益（EPS）73.57グロス・マージン50.05%純利益率13.97%有利子負債／自己資本比率7.4%4YC の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.1%現在の配当利回り30%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/16 03:26終値2026/07/16 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋M3, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Ritsuo WatanabeBofA Global ResearchLuoxin JiangCitic Securities Co., Ltd.Shuo SongCitic Securities Co., Ltd.18 その他のアナリストを表示
お知らせ • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026
お知らせ • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026
お知らせ • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026
お知らせ • Jun 09M3, Inc. to Report Q1, 2027 Results on Aug 06, 2026M3, Inc. announced that they will report Q1, 2027 results on Aug 06, 2026
お知らせ • Jun 05M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK.M3, Inc. (TSE:2413) signed Share Transfer Agreement to acquire Wiseman Co. Ltd from Soichiro Minamidate and MMK GK on June 5, 2026. For the period ending June 30, 2025, Wiseman Co. Ltd reported total revenue of ¥12.38 billion, operating loss of ¥222 million and net loss of ¥170 million. As of June 30, 2025, Wiseman Co. Ltd reported total assets of ¥20.03 billion and total common equity of ¥2.74 billion. The expected completion of the transaction is July 1, 2026.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Satoko Suzuki was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 02M3, Inc., Annual General Meeting, Jun 26, 2026M3, Inc., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 22M3, Inc. to Report Fiscal Year 2026 Results on May 01, 2026M3, Inc. announced that they will report fiscal year 2026 results on May 01, 2026
お知らせ • Nov 29M3, Inc. to Report Q3, 2026 Results on Feb 04, 2026M3, Inc. announced that they will report Q3, 2026 results on Feb 04, 2026
お知らせ • Sep 04Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion.Intermestic Inc. (TSE:262A) agreed to acquire Horus Co., Ltd. from M3, Inc. (TSE:2413), NIC Fund II Cayman, LP, Camellia Fund 2 Cayman L.P., Kerasus Fund 2 Cayman L.P., Wisteria Fund II Cayman, LP and Horus IE Limited Liability Partnership for ¥19.1 billion on September 2, 2025. A cash consideration of ¥19.08 billion will be paid by Intermestic Inc. As part of consideration, ¥19.08 billion is paid towards common equity of Horus Co., Ltd. The transaction will be financed through senior debt of ¥18 billion. For the period ending April 30, 2025, Horus Co., Ltd. reported total revenue of ¥28.19 billion and EBIT of ¥1.84 billion. As of April 30, 2025, Horus Co., Ltd. reported total assets of ¥19.95 billion and total common equity of ¥4.42 billion. The expected completion of the transaction is October 1, 2025.
お知らせ • Sep 01M3, Inc. to Report Q2, 2026 Results on Nov 12, 2025M3, Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Jun 05EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders.EUCALIA Inc. (TSE:286A) signed an agreement to acquire Epigno Inc. from a group of shareholders on June 5, 2025. EUCALIA Inc acquired 0.053 shares in Epigno Inc. The sellers were 19.9% stake from M3, Inc., 9.4% stake from M3 Career, Inc., 11.7% stake from THVP-No. 1 Limited Partnership, a fund managed by Tohoku University Venture Partners Co.,Ltd., 22.5% stake from Fumiyoshi Inui,12.1% stake from Takuya Shiga. The other sellers were Lifetime Ventures Investment LP, Kanshin Mirai No.2 Investment LP, Healthcare New Frontier Investment LP, and Colopl Next No.7 Fund Investment LP. For the period ending August 31, 2024, Epigno Inc. reported total revenue of approximately ¥110 million, operating loss of ¥83.7 million, net loss of ¥81.19 million, total assets of approximately ¥190 million and net assets of ¥23.3 million. The transaction is expected to close on July 1, 2025.
お知らせ • May 31M3, Inc. to Report Q1, 2026 Results on Aug 06, 2025M3, Inc. announced that they will report Q1, 2026 results on Aug 06, 2025
お知らせ • May 03M3, Inc. (TSE:2413) announces an Equity Buyback for 20,000,000 shares, representing 2.95% for ¥20,000 million.M3, Inc. (TSE:2413) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 2.95% of its total shares outstanding (excluding treasury shares), for a total of ¥20,000 million. The purpose of repurchase program is to provide returns to shareholders. The repurchase program is valid till April 30, 2026. As of March 31, 2025, the company had 679,032,629 shares issued (excluding treasury shares) and 45,271 treasury shares
お知らせ • May 02+ 2 more updatesM3, Inc., Annual General Meeting, Jun 26, 2025M3, Inc., Annual General Meeting, Jun 26, 2025.
お知らせ • Mar 07M3, Inc. (TSE:2413) entered into Share transfer agreement to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion.M3, Inc. (TSE:2413) agreed to acquire 51% stake in Ewel Inc. from Tokyu Land Corporation for ¥10.2 billion on March 5, 2025. A cash consideration of ¥10.2 billion will be paid by M3, Inc. As part of consideration, ¥10.2 billion is paid towards common equity of Ewel Inc. The transaction will be financed through Cash on Hand of ¥10.2 billion. For the period ending March 31, 2024, Ewel Inc. reported total revenue of ¥11.67 billion, EBIT of ¥887 million and net income of ¥566 million. As of March 31, 2024, Ewel Inc. reported total assets of ¥13.65 billion and total common equity of ¥5.88 billion. The expected completion of the transaction is April 1, 2025.
お知らせ • Mar 01M3, Inc. to Report Fiscal Year 2025 Results on May 02, 2025M3, Inc. announced that they will report fiscal year 2025 results on May 02, 2025
お知らせ • Feb 10M3, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025M3, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the period, the company expected revenue to be in the range of JPY 268,000 million to JPY 273,000 million, operating profit to be in the range of JPY 67,000 million to JPY 70,000 million, profit attributable to owners of the parent to be in the range of JPY 44,000 million to JPY 46,000 million and basic earnings per share to be in the range of JPY 64.80 to JPY 67.75.
お知らせ • Nov 30M3, Inc. to Report Q3, 2025 Results on Feb 10, 2025M3, Inc. announced that they will report Q3, 2025 results on Feb 10, 2025
Reported Earnings • Nov 01Second quarter 2025 earnings released: EPS: JP¥8.90 (vs JP¥16.19 in 2Q 2024)Second quarter 2025 results: EPS: JP¥8.90 (down from JP¥16.19 in 2Q 2024). Revenue: JP¥60.6b (up 3.8% from 2Q 2024). Net income: JP¥6.05b (down 45% from 2Q 2024). Profit margin: 10.0% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe.
Valuation Update With 7 Day Price Move • Oct 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €10.30, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €13.60 per share.
お知らせ • Aug 27M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024M3, Inc. announced that they will report Q2, 2025 results on Oct 30, 2024
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €8.75, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €14.82 per share.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €7.45, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €14.26 per share.
Reported Earnings • Jul 29First quarter 2025 earnings released: EPS: JP¥16.57 (vs JP¥18.29 in 1Q 2024)First quarter 2025 results: EPS: JP¥16.57 (down from JP¥18.29 in 1Q 2024). Revenue: JP¥64.2b (up 12% from 1Q 2024). Net income: JP¥11.2b (down 9.4% from 1Q 2024). Profit margin: 18% (down from 22% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jun 03M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024M3, Inc. announced that they will report Q1, 2025 results on Jul 26, 2024
Reported Earnings • May 01Full year 2024 earnings released: EPS: JP¥66.68 (vs JP¥72.22 in FY 2023)Full year 2024 results: EPS: JP¥66.68 (down from JP¥72.22 in FY 2023). Revenue: JP¥238.9b (up 3.5% from FY 2023). Net income: JP¥45.3b (down 7.7% from FY 2023). Profit margin: 19% (down from 21% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Apr 28+ 1 more updateM3, Inc., Annual General Meeting, Jun 26, 2024M3, Inc., Annual General Meeting, Jun 26, 2024.
Buy Or Sell Opportunity • Apr 25Now 20% overvaluedOver the last 90 days, the stock has fallen 25% to €11.20. The fair value is estimated to be €9.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Board Change • Mar 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 11 non-independent directors. Independent External Director Yusuke Tsugawa was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
